Resverlogix (TSX:RVX) Other Stockholders Equity : C$-0.00 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Other Stockholders Equity?

Resverlogix's Other Stockholders Equity for the quarter that ended in Mar. 2024 was C$-0.00 Mil.

Resverlogix's quarterly Other Stockholders Equity increased from Sep. 2023 (C$-0.00 Mil) to Dec. 2023 (C$0.00 Mil) but then declined from Dec. 2023 (C$0.00 Mil) to Mar. 2024 (C$-0.00 Mil).

Resverlogix's annual Other Stockholders Equity increased from Dec. 2021 (C$-0.00 Mil) to Dec. 2022 (C$0.00 Mil) and increased from Dec. 2022 (C$0.00 Mil) to Dec. 2023 (C$0.00 Mil).

Resverlogix Other Stockholders Equity Historical Data

The historical data trend for Resverlogix's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Other Stockholders Equity Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

1.64

2.09

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Resverlogix Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Resverlogix Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Resverlogix's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines